DYNC1I2 Antikörper (AA 129-366)
DYNC1I2
Reaktivität: Human
WB, IF/ICC
Wirt: Kaninchen
Polyclonal
unconjugated
Produktnummer ABIN2800488
-
-
Target
Alle DYNC1I2 Antikörper anzeigen
-
DYNC1I2
(Dynein, Cytoplasmic 1, Intermediate Chain 2 (DYNC1I2))
-
Bindungsspezifität
-
AA 129-366
-
Reaktivität
-
Human
-
Wirt
-
Kaninchen
-
Klonalität
-
Polyklonal
-
Konjugat
-
Dieser DYNC1I2 Antikörper ist unkonjugiert
-
Applikation
-
Western Blotting (WB), Immunofluorescence (fixed cells) (IF/ICC)
-
Verwendungszweck
-
DYNC1I2 antibody, 0.3 mg/ml
-
Immunogen
-
Recombinant protein fragment contain a sequence corresponding to a region within amino acids 129-366 (Q13409) of DYNC1I2
-
Isotyp
-
IgG
-
Top Product
-
Discover our top product DYNC1I2 Primärantikörper
-
-
-
Applikationshinweise
-
ICC/IF,Western blot
-
Beschränkungen
-
Nur für Forschungszwecke einsetzbar
-
-
Format
-
Liquid
-
Konzentration
-
0.3 mg/mL
-
Buffer
-
0.1M Tris, 0.1M Glycine, 10 % Glycerol ( pH 7). 0.01 % Thimerosal was added as a preservative.
-
Konservierungsmittel
-
Thimerosal (Merthiolate)
-
Vorsichtsmaßnahmen
-
This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
-
-20 °C
-
Informationen zur Lagerung
-
-20°C
-
-
Target
-
DYNC1I2
(Dynein, Cytoplasmic 1, Intermediate Chain 2 (DYNC1I2))
-
Andere Bezeichnung
-
DYNC1I2 (DYNC1I2 Produkte)
-
Synonyme
-
dnci2 antikoerper, dncic1 antikoerper, ic2 antikoerper, dync1i2 antikoerper, im:7147021 antikoerper, zgc:153318 antikoerper, 3110079H08Rik antikoerper, AW554389 antikoerper, Dncic2 antikoerper, Dnci2 antikoerper, DNCI2 antikoerper, IC2 antikoerper, dynein, cytoplasmic 1, intermediate chain 2 antikoerper, dynein, cytoplasmic 1, intermediate chain 2 S homeolog antikoerper, dynein cytoplasmic 1 intermediate chain 2 antikoerper, dynein, cytoplasmic 1, intermediate chain 2a antikoerper, dync1i2 antikoerper, dync1i2.S antikoerper, DYNC1I2 antikoerper, dync1i2a antikoerper, Dync1i2 antikoerper
-
Molekulargewicht
-
71 kDa
-
Gen-ID
-
1781
-
Pathways
-
M Phase
-